Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma by Tilly, Hervé et al.
doi:10.1182/blood-2003-02-0542 






Georges Fillet, Catherine Guettier, Thierry Jo Molina, Christian Gisselbrecht and Félix Reyes 
Hervé Tilly, Eric Lepage, Bertrand Coiffier, Michel Blanc, Raoul Herbrecht, André Bosly, Michel Attal,
 
 standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
Intensive conventional chemotherapy (ACVBP regimen) compared with
 http://bloodjournal.hematologylibrary.org/cgi/content/full/102/13/4284
Updated information and services can be found at: 
 (2501 articles)Clinical Trials and Observations 
 (4223 articles)Neoplasia 
 collections: BloodArticles on similar topics may be found in the following 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at: 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints
Information about ordering reprints may be found online at: 
 http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl
Information about subscriptions and ASH membership may be found online at: 
. Hematology; all rights reservedCopyright 2007 by The American Society of 
200, Washington DC 20036.
semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 





 For personal use only. by YVES BEGUIN on February 3, 2009. www.bloodjournal.orgFrom 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Intensive conventional chemotherapy (ACVBP regimen) compared with standard
CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
Herve´ Tilly, Eric Lepage, Bertrand Coiffier, Michel Blanc, Raoul Herbrecht, Andre´ Bosly, Michel Attal, Georges Fillet, Catherine Guettier,
Thierry Jo Molina, Christian Gisselbrecht, and Fe´lix Reyes, for the Groupe d’Etude des Lymphomes de l’Adulte
We conducted a randomized trial to com-
pare the intensive conventional chemo-
therapy regimen ACVBP (doxorubicin, cy-
clophosphamide, vindesine, bleomycin,
prednisone) with standard CHOP (cyclo-
phosphamide, doxorubicin, vincristine,
and prednisone) in previously untreated
patients with poor-risk aggressive lym-
phoma. Patients aged 61 to 69 years who
had aggressive non-Hodgkin lymphoma
with at least one prognostic factor of the
age-adjusted international prognostic in-
dex (IPI) were included. ACVBP consisted
of an induction phase of intensified che-
motherapy and central nervous system
(CNS) prophylaxis followed by a sequen-
tial consolidation phase. Of the 708 pa-
tients registered for the study, 635 were
eligible. The rate of complete response
was 58% in the ACVBP group and 56% in
the CHOP group (P  .5). Treatment-
related death occurred in 13% of the
ACVBP group and 7% of the CHOP group
(P  .014). At 5 years, the event-free sur-
vival was 39% in the ACVBP group and
29% in the CHOP group (P  .005). The
overall survival was significantly longer
for patients treated with ACVBP, at 5
years it was 46% compared with 38% for
patients treated with CHOP (P  .036).
CNS progressions or relapses were more
frequent in the CHOP group (P  .004).
Despite higher toxicity, the ACVBP regi-
men, used as first-line treatment for pa-
tients with poor-risk aggressive lym-
phoma, is superior to standard CHOP
with regard to both event-free survival
and overall survival. (Blood. 2003;102:
4284-4289)
© 2003 by The American Society of Hematology
Introduction
The incidence of non-Hodgkin lymphoma, especially that of aggressive
histology, is steadily increasing.1 However, during the last 30 years,
improvement in treatment outcome remained modest2 and less than
50% of the patients with aggressive lymphoma are cured.
The standard treatment used since the 1970s is the CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone) che-
motherapy regimen,3 delivering 8 cycles at a 3-week interval in
advanced disease. Subsequently, new combinations including addi-
tional non–cross-reacting drugs such as methotrexate, bleomycin,
or cytarabine have been proposed.4-6 However, multicenter random-
ized trials failed to demonstrate any survival advantage of these
second- and third-generation regimens over the standard CHOP.7,8
Since 1980, the Groupe d’Etudes des Lymphomes (GELA) has
developed a chemotherapy schedule, the ACVBP (doxorubicin,
cyclophosphamide, vindesine, bleomycin, prednisone) regimen,
which consisted of an induction phase of 4 cycles of intensified
CHOP with central nervous system (CNS) prophylaxis followed by
a sequential consolidation phase.9,10 In a previous study, the
comparison of this regimen with m-BACOD (cyclophosphamide,
doxorubicin, vincristine, bleomycin, methotrexate, and dexametha-
sone), a third-generation regimen, in patients with low-risk aggres-
sive lymphoma, showed that ACVBP could be beneficial for
patients with more advanced disease.11
Therefore, in 1993, the GELA initiated a phase 3 study
comparing ACVBP to CHOP in patients with poor-prognosis
aggressive lymphoma. We restricted this trial to patients aged
between 61 and 69 years because another study from our group had
shown that patients younger than 60 years of age with poor-risk
aggressive lymphoma could benefit from consolidative high-dose
therapy with stem cell rescue in the front-line regimen.12
Patients, materials, and methods
Patients
Newly diagnosed patients between 61 and 69 years of age with diffuse
mixed, diffuse large-cell, immunoblastic, lymphoblastic, or Burkitt lym-
phoma were eligible for the present study providing that they had at least
one adverse prognostic factor as defined by the age-adjusted international
prognostic index (IPI) for non-Hodgkin lymphoma (namely stage III or IV
disease, elevated lactate dehydrogenase [LDH] level and Eastern Coopera-
tive Oncology Group [ECOG] performance status of 2 to 4).13
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Patients were not included if they had any of the following conditions:
lymphoblastic or Burkitt lymphoma with bone marrow or CNS involve-
ment; primary cerebral lymphoma; history of low-grade lymphoma;
positive serology to human immunodeficiency virus; previous treatment
with chemotherapy, radiotherapy, or organ transplantation; concomitant or
previous cancer (except in situ cervix carcinoma or skin epithelioma);
congestive heart failure; recent myocardial infarction or conduction abnor-
malities; uncontrolled diabetes mellitus; and liver or kidney failure. This
study was approved by the Hoˆpital Saint Louis (Paris, France) institutional
review board. Informed consent was provided according to the Declaration
of Helsinki.
Histologic analysis
A review of histologic material by 2 independent pathologists from the
GELA was planned in the protocol and carried out in 92% of the enrolled
patients. Lymphomas were initially classified according to the Working
Formulation.14 Results were subsequently converted by the committee
pathologists according to the new World Health Organization (WHO)
classification.15
Staging
The extent of the disease was studied by physical examination, computer-
ized tomographic scan of chest and abdomen, cerebrospinal fluid examina-
tion, bone marrow biopsy, and other investigational procedures according to
clinical symptoms. The number of extranodal sites and the diameter of the
largest tumor mass were determined. Patients were staged according to the
Ann Arbor classification. Performance status was assessed according to the
ECOG scale (0 to 4).16 Serum LDH level was expressed as the ratio over the
maximum normal value.
Treatments
After giving written informed consent, patients were randomly assigned to
receive either ACVBP or CHOP regimen. The ACVBP regimen consisted of
4 induction courses given every 3 weeks of doxorubicin (75 mg/m2) on day
1, cyclophosphamide (1200 mg/m2) intravenously on day 1, vindesine (2
mg/m2) on days 1 and 5, bleomycin (10 mg) on days 1 and 5, prednisone (60
mg/m2) orally from day 1 to day 5, and intrathecal methotrexate (15 mg) on
day 2. Granulocyte-macrophage or granulocyte colony-stimulating factor
was administered subcutaneously on days 6 through 13 of each cycle.17
Patients then received a sequential consolidation therapy with 2 courses of
intravenous methotrexate (3 g/m2) plus leucovorin rescue, 4 courses of
etoposide (300 mg/m2) and ifosfamide (1500 mg/m2) with mesna protec-
tion, and 2 courses of cytosine-arabinoside (100 mg/m2) subcutaneously for
4 days, each consolidation course being administered at a 14-day interval.
The CHOP regimen was administered as described by Coltman et al,3
namely 8 cycles with a 3-week interval of doxorubicin (50 mg/m2)
intravenously on day 1, cyclophosphamide (750 mg/m2) intravenously on
day 1, vincristine (1.4 mg/m2) intravenously on day 1 (with the dose capped
at 2.0 mg), and prednisone (40 mg/m2) orally from day 1 to day 5. No
growth factor support and no CNS prophylaxis were planned in this group.
In each treatment arm no dose adjustment was planned according to
hematologic toxicity, but courses were postponed until leukocyte count rose
above 2.0  109/L and platelet count rose above 100  109/L. The ECOG
criteria were used to evaluate toxicity.16
Dose intensity of drugs could be compared only for doxorubicin and
cyclophosphamide during the 4 first cycles of each treatment regimen. The
received dose intensity was calculated as previously described.18
Response
In each treatment arm, response was assessed by repeat staging 4 weeks
after the therapy ended. Disappearance of all lesions and laboratory
abnormalities related to the lymphoma-defined complete remission (CR). A
decrease of more than 75% of the measurable lesions with disappearance of
laboratory abnormalities was considered as unconfirmed CR (CRu).19
Partial response (PR) was defined by a 50% to 75% regression of the tumor
size. Stable disease was defined by regression by less than 50% of any
measurable lesion. Patients who had progressive disease at any time were
considered as failure and were given other treatment at the discretion of the
treating physician.
Statistical methods
Study design. This study was a prospective, randomized study. Randomization
was stratified according to the participating centers by sets of 4 successive
patients. The randomization was generated by the GELA program coordinating
center, which issued treatment allocation by telephone after confirmation of the
patient eligibility. Case report forms collected at participating centers were sent to
the coordinating center and keyed-in twice for verification. Outliers and
erroneous values were checked routinely.
The main objective of the trial was to detect a 10% difference between
ACVBP and CHOP regimens on the assumption of a 25% 2-year event-free
survival rate in the CHOP arm (2-sided test: type I error of 0.05, type II error
of 0.10). Secondary end points were response to treatment, toxicity,
disease-free survival, number of CNS relapse, and overall survival. This
design required the randomization of 600 eligible patients.
Statistical analyses. The stopping date was August 1, 2001. Patient
characteristics, complete remission rates, and frequencies of adverse
reactions were compared by the chi-square and Fisher exact tests.20
Event-free survival was measured from the date of randomization to disease
progression, relapse, or death from any cause or the stopping date.
Disease-free survival was measured from the date of remission to either
relapse or death from any cause or the stopping date. Overall survival
was measured from the date of randomization to either death from any
cause or the stopping date. When the stopping date was not reached, data
were censored at the date of the last follow-up evaluation. The survival
functions were estimated by the Kaplan-Meier method21 and compared
by log-rank test.22 Cox proportional hazards model23 was used to assess
treatment effect controlling for the values of the age-adjusted IPI.13
Tests for comparison were regarded as significant if the 2-sided P value
was less than .05.
Results
Patient characteristics
Between March 1993 and June 1998, 708 patients were registered
for the study by the 84 participating centers. Seventy-three patients
(ACVBP group, 36; CHOP group, 37) were considered ineligible
for the following reasons: incorrect histology as determined by
central review, 50 patients (carcinoma, 7; Hodgkin disease, 5;
lymphocytic lymphoma, 7; follicular lymphoma, 22; mantle cell
lymphoma, 8; other lymphoma, 1); Burkitt lymphoma with bone
marrow involvement, 1 patient; positive serology for HIV, 4
patients; age-adjusted IPI equal to 0, 3 patients; younger than 61
years of age, 11 patients; and previous cancer, 4 patients. Thus, 635
patients were eligible for analysis; 323 patients were allocated to
ACVBP treatment and 312 to CHOP. As shown in Table 1, the 2
groups were well balanced with respect to major prognostic factors.
Response to treatment
Response to treatment could be assessed in 612 patients (96%). The
rate of complete response (CR and CRu) was 58% in the ACVBP
group and 56% in the CHOP group (P  .5). The mean received
dose intensity of doxorubicin during the first 4 cycles of treatment
was 23.0 mg per square meter per week (92% of the designed dose
intensity) in the ACVBP group and 15.7 mg per square meter per
week (94% of the designed dose intensity) in the CHOP group,
respectively. The mean received dose intensity of cyclophospha-
mide was 372 mg per square meter per week (93% of the designed
dose intensity) in the ACVBP group and 238 mg per square meter
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per week (95% of the designed dose intensity) in the CHOP group,
respectively.
Event-free survival
The median follow-up was 68 months. As shown on Figure 1, the
event-free survival was significantly longer for patients treated
with ACVBP (P  .005). The 5-year estimated event-free survival
rates were 39% in the ACVBP group (95% confidence interval,
0.34 to 0.45) and 29% in the CHOP group (95% confidence
interval, 0.24 to 0.34). This difference remained statistically
significant in an intent-to-treat analysis of the 708 patients regis-
tered for the study (P  .007), in an analysis of the 649 patients
who had a central pathology review (P  .004) and in an analysis
of the 618 eligible patients remaining after exclusion of the Burkitt
and lymphoblastic histologies (P  .005) as shown on Figure 2.
In a multivariate analysis, the treatment group was found to
affect event-free survival independently of the age-adjusted IPI
(P  .003; risk ratio, 1.34; 95% confidence interval, 1.09 to
1.61). Nine CNS progressions or relapses occurred in the
ACVBP group compared with 26 in the CHOP group (P  .002;
risk ratio, 2.99; 95% confidence interval, 1.48 to 6.03). As
shown in Table 2, most of these progressions occurred during
treatment and were restricted to CNS.
Disease-free survival
Sixty-three of the 177 patients in complete remission in the
ACVBP group relapsed compared with 95 of the 171 patients in the
CHOP group. At 5 years, the estimated disease-free survival rates
were 62% (95% confidence interval, 0.54 to 0.70) in the ACVBP
group and 44% (95% confidence interval, 0.36 to 0.52) in the
CHOP group (P  .0002) (Figure 3).
Overall survival
There were 175 deaths among the patients treated with ACVBP and
200 among those treated with CHOP (Figure 4). The 5-year
estimated survival rates were 46% in the ACVBP group (95%
confidence interval, 0.40 to 0.52) and 38% in the CHOP group
(95% confidence interval, 0.32 to 0.43). The difference in overall
survival between the 2 treatment groups was statistically significant
(P  .036). This difference remained significant in an intent-to-
treat analysis of the 708 patients registered (P  .039), in an
analysis of the 649 patients who had a central pathology review
(P  .023), and in an analysis of the 618 eligible patients remain-
ing after exclusion of the Burkitt and lymphoblastic histologies
Figure 2. Estimated event-free survival after exclusion of patients with Burkitt
and lymphoblastic lymphoma according to treatment group (P  .005).





n 312 (%) P
Median age, y 65 65
Sex 0.9
Male 182 (56) 177 (57)
Female 141 (44) 135 (43)
Histology 0.8
Diffuse large B cell 257 (80) 244 (78)
Burkitt 5 (1) 6 (2)
Lymphoblastic 3 (1) 3 (1)
Peripheral T-cell NOS 29 (9) 28 (9)
Angio-immunoblastic T cell 8 (2) 11 (4)
Anaplastic large-cell T/NK 12 (4) 10 (3)
Aggressive unclassifiable 9 (3) 10 (3)
Immunophenotype* 0.5
B 263 (85) 253 (84)
T 47 (15) 49 (16)
B symptoms* 0.2
Absent 163 (51) 142 (46)
Present 155 (49) 168 (54)
Performance status (ECOG) 1
0-1 220 (68) 212 (68)
Greater than 1 103 (32) 100 (32)
Ann Arbor stage 0.6
I-II 56 (17) 59 (19)
III-IV 267 (83) 253 (81)
Number of extranodal sites* 0.8
0-1 163 (51) 156 (50)
More than 1 155 (49) 156 (50)
Sites of extranodal involvement*
Bone marrow 78 (24) 96 (31) 0.08
Liver 34 (10) 44 (14) 0.2
Spleen 78 (24) 75 (24) 0.9
Skin 24 (7) 14 (4) 0.1
Lungs 27 (8) 39 (12) 0.09
Head and Neck 34 (11) 28 (9) 0.5
Epidural involvement 9 (3) 10 (3) 0.8
Serum LDH level 0.1
N or less 92 (28) 71 (23)
Greater than N 231 (72) 241 (77)
Serum albumin level* 0.4
Less than 35 g/L 169 (56) 151 (52)
35 g/L or greater 133 (44) 138 (48)
Number of age-adjusted IPI factors 0.6
1 113 (35) 105 (34)
2 142 (44) 130 (42)
3 68 (21) 77 (24)
NOS indicates not otherwise specified; NK, natural killer; N, normal value; and
IPI, international prognostic index for aggressive lymphoma.13
*Data were unavailable for some patients.
Figure 1. Estimated event-free survival according to treatment group (P  .005).
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(P  .039) (Figure 5). In a multivariate analysis, this advantage in
overall survival appeared to be independent of the age-adjusted IPI
(P  .028; risk ratio, 1.26; 95% confidence interval, 1.01 to 1.53).
Toxicity
As shown in Table 3, the patients treated with ACVBP had a higher
rate of leukopenia, thrombocytopenia as well as infection, and
mucositis than those treated with CHOP. The incidence of grade 3
and 4 leukopenia and thrombocytopenia was significantly higher in
the ACVBP group (P  .001) leading to a higher incidence of
severe or life-threatening infections (P  .001). Treatment-related
deaths were significantly more frequent in the ACVBP group with
43 deaths (infectious complication, 28; methotrexate overdose or
allergy, 4; cerebral vascular accident, 3; hepatic failure, 2; cardiac
failure, 2; pulmonary toxicity, 1; bowel occlusion, 1; unexplained
death, 2) compared with 23 deaths among patients treated with
CHOP (infectious complication, 14; cerebral vascular accident, 3;
hepatic failure, 1; pulmonary toxicity, 1; tumor lysis syndrome, 1;
unexplained death, 3) (P  .014). In an explanatory multivariate
analysis, performance status greater than 2 at the time of diagnosis
was found to be the most important factor influencing the risk of
treatment-related death in both groups (ACVBP; P .0004, CHOP;
P  .0003, respectively). In addition, an age older than 65 years
was also correlated with this risk in the ACVBP group (ACVBP;
P  .004, CHOP; P  .98, respectively).
Discussion
In this randomized trial, we found a significant survival benefit
for patients with poor-prognosis aggressive non-Hodgkin lym-
phoma who were treated with the ACVBP regimen compared
with those treated with standard CHOP. As the complete
remission rates were similar in the 2 treatment groups, the
advantage in the ACVBP appeared to be related to a longer
disease-free survival, with an 18% difference at 5 years. Several
randomized studies have compared CHOP with modified CHOP-
like regimens24-26 or other chemotherapy combinations as m-
BACOD, MACOP-B (methotrexate, doxorubicin, cyclophospha-
mide, vincristine, bleomycin, prednisone), or PROMACE-
CytaBOM (prednisone, doxorubicin, cyclophosphamide,
etoposide, cytarabine, bleomycin, vincristine).7,8,27-30 With the
exception of the study from the Australian and New Zealand
Lymphoma Group,30 all of the studies failed to show any
advantage of the new regimen.
A small proportion of patients included in this trial had a
lymphoblastic or a Burkitt lymphoma without marrow or CNS
involvement. These patients are now treated in specific pro-
grams but, at the time of trial activation, previous GELA studies
had shown that the outcome of such patients with lymphoblastic
lymphoma treated with either CHOP, ACVBP, or a leukemia-
derived scheme did not differ31 and that the outcome of patients
with Burkitt lymphoma treated with ACVBP was similar to
those of patients with other aggressive lymphomas.32 The
exclusion of patients with lymphoblastic or Burkitt histology
from survival studies did not modify the results of the present
Figure 4. Estimated overall survival according to treatment group (P  .036).
Figure 5. Estimated overall survival after exclusion of patients with Burkitt and
lymphoblastic lymphoma according to treatment group (P  .039).
Table 2. Characteristics of the central nervous system recurrences




Diffuse large B cell 7 21
Lymphoblastic 0 1
Peripheral T cell 1 2
Aggressive unclassifiable 1 2
Occurrence
On therapy 6 21
Off therapy 3 5
Isolated CNS recurrence 7 18





CNS indicates central nervous system.
Figure 3. Estimated disease-free survival for patients in complete remission
according to treatment group (P  .0002).
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study. Major prognostic factors were well balanced between the
treatment groups. A nonsignificant excess of bone marrow and
lung involvement was noted in the CHOP group but this did not
translate into unbalanced numbers of extranodal sites or reparti-
tion of IPI factors.
It is not yet clear which part of the ACVBP regimen is the most
important in reducing the risk of relapse. Influence of dose intensity
on treatment outcome in aggressive non-Hodgkin lymphoma is
debatable. Several retrospective studies have shown that a decrease
in dose intensity, compared with the planned schedule, was
associated with a decreased response rate and a shorter sur-
vival.18,33,34 However, a prospective study failed to demonstrate
that increasing dose intensity might positively influence outcome.35
Only recently, the German Lymphoma Study Group has shown that
shortening intervals between CHOP cycles could improve treat-
ment results.36 Our trial was not designed as a dose intensity study
but the received dose intensity of doxorubicin and cyclophospha-
mide during the first 4 cycles was respectively 46% and 56% higher
in the patients treated with ACVBP.
The sequential consolidation phase of ACVBP regimen intro-
duces drugs not administered during the induction phase of
treatment, such as high-dose methotrexate, etoposide, ifosfamide,
and cytosine-arabinoside. Except for the usual risks related to
high-dose methotrexate,37 toxicity of this phase is reduced and it is
delivered in an outpatient setting. Although high-dose therapy with
stem cell rescue has been shown to be superior to this sequential
consolidation phase in younger responding patients with poor-risk
lymphoma,12 2 prospective studies from our group failed to
demonstrate a benefit of a conventional intensification of this
phase.10,38
CNS recurrence is an almost uniformly fatal complication in
aggressive lymphoma. Its incidence in patients treated with
CHOP or CHOP-like regimens ranges from 5% to 11%.39 Risk
factors for CNS relapse are advanced stage, involvement of
more than one extranodal site, elevated LDH level, and poor
performance status, all factors identified in the IPI.13 In the
present study, these risk factors were equally balanced between
the treatment groups. By contrast, the incidence of isolated CNS
relapse in patients with aggressive lymphoma treated with
ACVBP regimen has been estimated to be 1.6%.40 In this
regimen, a CNS prophylaxis is administered, consisting of 4
intrathecal injections of methotrexate during induction followed
by 2 consolidative courses of high-dose intravenous metho-
trexate. Results of the present trial confirm that such a prophy-
laxis is necessary in patients with poor-risk aggressive lym-
phoma. As only one patient with lymphoblastic lymphoma
experienced a CNS relapse after CHOP therapy, it is unlikely
that inclusion of such patients in this trial could have influenced
this risk.
The first cycles of ACVBP have a regular hematologic toxicity,
a grade 4 leukopenia being the rule in this population of patients
older than 60 years of age. Growth factors reduce the duration of
leukopenia and decrease the risk of severe and life threatening
infection.17 However, in this trial, severe or fatal infections
occurred in 36% of the patients treated with ACVBP compared
with 15% of those treated with CHOP. This justifies a close
monitoring of patients treated with ACVBP in the early phase of the
treatment, especially those with an initial poor performance status
or those older than 65 years of age. As toxicity is strongly reduced
in patients younger than 60 years of age,9-12 it is reasonable to
assume that the advantage of ACVBP over standard CHOP should
be confirmed in this population.
We have recently shown that the addition of rituximab, a
monoclonal anti-CD20 antibody, to CHOP prolongs survival of
elderly patients with diffuse large B-cell lymphoma.41 These results
have prompted us to investigate the association of rituximab and
ACVBP in patients younger than 65 years of age.
We conclude that, in patients with poor-risk aggressive lym-
phoma, the ACVBP regimen significantly improves event-free and
overall survival compared with CHOP, despite its higher toxicity,
especially in patients older than 65 years of age. A prophylaxis of
CNS relapse is mandatory in this population.
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1 2 3 4 5 1 2 3 4 5
Leukopenia 0.3 1.7 5.1 91.5 0 3.6 8.6 19.0 53.8 0 .001
Thrombocytopenia 5.9 13.4 19.3 48.3 0 9.8 6.9 4.7 10.6 0 .001
Infection 13.9 33.7 18.1 8.1 8.7 13.9 21.0 8.1 2.0 4.5 .001
Mucositis 10.3 16.0 20.7 10.0 0 8.7 11.9 3.8 0.7 0 .001
Cardiac 3.0 5.0 2.7 2.0 0.6 3.8 3.1 3.1 0.3 0.6 .2
Hepatic 8.8 5.4 1.4 0.6 0.6 3.8 3.1 3.1 0.3 0.3 .5
Neurologic 8.5 7.8 2.7 0.9 0.9 14.6 9.0 3.8 2.1 0.9 .1
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